Phase II study of preoperative Docetaxel, cisplatin and S-1 in patients with clinically respectable type 4 , large type 3 and with extensive lymph node metastasis gastric cancer

Phase II study of preoperative Docetaxel, cisplatin and S-1 in patients with clinically respectable type 4 , large type 3 and with extensive lymph node metastasis gastric cancer - A Phase 2 study of preoperative Docetaxel, Cisplatin and S-1 therapy for locally advanced gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003052

Enrollment

Registered

2010-01-18

Start date

2009-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Preoperative chemotherapy with Docetaxel, cisplatin and S-1 followed by surgery.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)histologically confirmed gastric adenocarcinoma. 2)Macroscopically large Type3 or Type4 gastric cancer or any Type of gastric cancer with massive Lymph-node metastasis 3)No evidence of peritoneal dissemination by diagnostic laparoscopy.(within 4week to entry) 4)Clinically Possible to curative resection. 5)Less than 3cm of esophageal invasion. 6)Age 20-80 years old 7)PS (ECOG) 0-1 8)No prior treatment 9)Sufficient oral intake 10)Adequate organ function 11)Written informed consent

Exclusion criteria

Exclusion criteria: 1)Active malignancy in other organ 2)Serious complications 3)Acute inflammation 4)Allergy or hyper sensitivity to any drugs 5)Motor weakness or peripheral nerve disorder 6)With pleural or cardiac effusion 7)Pregnant or breast feeding 8)Interstitial pneumonia or pulmonary fibrosis 9)Psychological disease which require treatment 10)Hypersensitivity to S1 or CDDP or TXT 11)Systemic administration of other fluorouracil 12)Administration of flucytocine 13)Patients judged inappropriate for the study by the physicians

Design outcomes

Primary

Measure	Time frame
Pathological response	—

Countries

Japan

Contacts

Public ContactHitoshi Murakami

Yokohama City University Department of Surgery

m_air_h@yokohama-cu.ac.jp045-787-2645

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026